Open AccessPhase I–II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines
Author(s) -
Patrizia Vici,
Alessandra Fabi,
Giulio Metro,
Domenico Sergi,
Diana Giannarelli,
Luigi Di Lauro,
Gerold Bepler,
Federica Tomao,
Francesco Cognetti,
Francesca Conti,
Massimo Lopez
Publication year - 2010
Publication title -
cancer chemotherapy and pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.112
H-Index - 111
eISSN - 1432-0843
pISSN - 0344-5704
DOI - 10.1007/s00280-010-1369-y
Subject(s) - gemcitabine , medicine , regimen , neutropenia , breast cancer , chemotherapy , anthracycline , paclitaxel , metastatic breast cancer , toxicity , gastroenterology , oncology , phases of clinical research , febrile neutropenia , cancer , urology
Paclitaxel (PACL) plus gemcitabine (GEM) is an effective regimen for advanced breast cancer patients pretreated with anthracyclines. A prolonged GEM infusion at a fixed dose rate (FDR) of 10 mg/m²/min produces higher levels of intracellular active metabolites of GEM when compared with a standard 30-min infusion. In the present phase I/II trial, we investigated the association of FDR GEM plus PACL.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom